Richard W. Paul & Associates’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$863K Buy
14,980
+105
+0.7% +$6.03K 0.26% 97
2026
Q1
$902K Sell
14,875
-240
-2% -$14K 0.3% 89
2025
Q4
$815K Buy
15,115
+1,196
+9% +$57.5K 0.27% 96
2025
Q3
$628K Buy
13,919
+426
+3% +$19.9K 0.21% 107
2025
Q2
$625K Buy
13,493
+2,049
+18% +$101K 0.23% 104
2025
Q1
$698K Sell
11,444
-133
-1% -$7.75K 0.27% 93
2024
Q4
$655K Sell
11,577
-3,488
-23% -$195K 0.24% 107
2024
Q3
$779K Sell
15,065
-211
-1% -$9.9K 0.28% 99
2024
Q2
$634K Buy
15,276
+625
+4% +$28K 0.24% 106
2024
Q1
$795K Buy
14,651
+2,860
+24% +$146K 0.32% 83
2023
Q4
$605K Buy
11,791
+3,973
+51% +$209K 0.25% 102
2023
Q3
$454K Sell
7,818
-3,369
-30% -$206K 0.21% 110
2023
Q2
$715K Buy
11,187
+405
+4% +$27.2K 0.31% 91
2023
Q1
$747K Buy
10,782
+5,598
+108% +$395K 0.34% 82
2022
Q4
$373K Buy
+5,184
New +$391K 0.19% 121

Other funds holding BMY

Richard W. Paul & Associates's BMY Position: Q2 2026 in Review

Richard W. Paul & Associates increased its Bristol-Myers Squibb (BMY) stake by 0.71% in Q2 2026, buying an estimated $6.03K and bringing the position to 14,980 shares worth $863K. The position accounts for 0.26% of the portfolio, ranked #97.

Richard W. Paul & Associates first reported a position in BMY in Q4 2022 and has held it in 15 quarters since. The position peaked at $902K in Q1 2026. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Richard W. Paul & Associates held 14,980 shares of Bristol-Myers Squibb worth $863K as of Q2 2026.
  • Richard W. Paul & Associates bought 105 Bristol-Myers Squibb shares in Q2 2026, an estimated $6.03K.
  • Bristol-Myers Squibb made up 0.26% of Richard W. Paul & Associates's portfolio in Q2 2026, its #97 holding.
  • Richard W. Paul & Associates first reported a position in Bristol-Myers Squibb in Q4 2022 and has held it in 15 quarters since.
  • Richard W. Paul & Associates's Bristol-Myers Squibb position peaked at $902K in Q1 2026.
  • 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Richard W. Paul & Associates's 13F filing for Q2 2026, filed 10 Aug 2026.